Trial Profile

A Phase 1 Study to Assess the Pharmacokinetics and Safety of Ascending Doses of JOTROL Oral Gelcaps in Healthy Subjects, and to Determine the Influence of Food

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 17 Aug 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Resveratrol (Primary)
Indications Alzheimer's disease
Focus Adverse reactions; First in man; Pharmacokinetics; Proof of concept

Most Recent Events

13 Jul 2022 Protocol amended as drug concentration changed from 1000mg to 500mg and time frame is from 8 weeks to Pre-dose and 0.133, 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, and 32 hours post-dose on Day 1 days in primary results.
13 Jul 2022 Status changed from recruiting to completed.
23 Feb 2022 Results published in the Jupiter Orphan Therapeutics Media Release

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com